Related Experiment Video
Updated: Jan 10, 2026
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral
T W Brettig1,2, A Young1,2,3, R Bhatia4,5
1National Allergy Centre of Excellence (NACE), Parkville, Victoria, Australia.
Insights
The ADAPT OIT Program offers a standardized approach to peanut oral immunotherapy (OIT) for Australian infants, aiming for widespread accessibility and improved outcomes in managing peanut allergy.
Area of Science:
- Allergy and Immunology
- Pediatric Gastroenterology
- Public Health Initiatives
Background:
- Peanut allergy is a prevalent and persistent condition in Australian children.
- Current access to disease-modifying oral immunotherapy (OIT) is limited globally and in Australia.
- Variability in OIT protocols hinders large-scale evaluation of safety and effectiveness.
Purpose of the Study:
- To establish a standardized national model of care for peanut OIT.
- To improve accessibility of OIT for infants with peanut allergy in Australia.
- To enable rigorous evaluation and optimization of OIT programs.
Main Methods:
- The ADAPT OIT Program was launched in July 2024, involving 10 pediatric hospitals.
- Infants with IgE-mediated peanut allergy were enrolled based on specific sensitization criteria.
- A standardized OIT protocol with dose escalation, maintenance, and assessment for sustained unresponsiveness (SU) was implemented.
Main Results:
- The program aims for broad accessibility of best-practice peanut OIT for infants.
- A standardized national model facilitates rigorous and timely evaluation.
- The program design allows for ongoing optimization to maximize impact.
Conclusions:
- The ADAPT OIT Program seeks to provide accessible, best-practice peanut OIT to many infants in Australia.
- A national standardized model with robust evaluation supports program optimization.
- This initiative aims to change the trajectory of peanut allergy management through accelerated tolerance pathways.
Introduction:
Peanut allergy is the most common food allergy in Australian school-aged children and is rarely outgrown. Access to oral immunotherapy (OIT), a disease-modifying treatment for food allergy, is limited in many regions of the world, including Australia. Clinical trials show high rates of allergic desensitisation and remission are being achieved, particularly in young children, but significant variability in protocols and implementation prevents large-scale evaluation of clinical and patient-reported safety, effectiveness and long-term outcomes. A standardised national model of care OIT program has not been previously attempted. In Australia, the National Allergy Centre of Excellence partnered with 10 paediatric hospitals to develop and implement the ADAPT OIT Program, which aims to change the trajectory from 'Allergy Development to an Accelerated Pathway to Tolerance'. The Program was designed after extensive international expert and consumer consultation, and attempts to be pragmatic, feasible by using existing resources, and equitable, with out-of-pocket costs to families limited to the purchase of the OIT product, store-bought peanut flour.
Methods:
In July 2024, the ADAPT OIT Program was launched. Infants were considered if they had a history consistent with an IgE-mediated allergic reaction to peanut < 12 months of age and evidence of sensitisation (peanut SPT ≥ 3 mm; peanut sIgE or ara h 2 sIgE ≥ 0.35kUA/L). A threshold oral food challenge (OFC) was done to confirm a diagnosis of peanut allergy using teaspoon measures (1/64th, 1/32nd, 1/16th, 1/8th, ¼, ½, 1 tsp. peanut flour, cumulative dose of 2435 mg peanut protein), and to determine the OIT starting dose unless the index reaction was a CoFAR Grade 3+. In this case, infants started OIT with a microdose escalation commencing with a red microspoon of peanut flour (3 mg peanut protein) up to a maximum of 1/64th tsp. (15 mg). Up-dose stage visits were conducted every 4 weeks until the maintenance stage was achieved (1/2 tsp. of peanut flour: 650 mg peanut protein). After 2 years of OIT, infants had an 8-week period of strict peanut avoidance followed by an OFC to assess for sustained unresponsiveness (SU). Infants were followed up for a minimum of 12 months post SU OFC.
Conclusion:
The ADAPT OIT Program aims to make best-practice peanut OIT accessible to a significant proportion of infants with peanut allergy in Australia. Under a national standardised model, with rigorous and timely evaluation, the Program design enables optimisation over time for maximal impact.
